MagnetOs Bone Grafts Approved in Australia
MagnetOs Granules and MagnetOs Putty received TGA approval in Australia. Initial market launch is scheduled for late 1Q21. Oct 05, 2020
Captiva Spine Granted U.S. Patent for Posterior SI Joint Fusion
The patent addresses Quadracentric carpentry which prepares the sacroiliac joint for an easy, repeatable SI joint fusion. Oct 01, 2020
Orthofix Granted Additional FDA Clearance for FIREBIRD SI Fusion
FIREBIRD SI Fusion System is the first 3D-printed titanium bone screw with nanotechnology to compress and stabilize the SI joint during fusion. Oct 01, 2020
SurGenTec Gains FDA Clearance for 3D GraftRasp System, Including Key Spine Indications
3D GraftRasp is the only device to receive FDA clearance for both decortication of bone and the delivery of autograft, allograft or synthetic bone graft. Oct 01, 2020
CurveBeam Gains CE Mark Approval for HiRise Weight-Bearing CT System for Lower Extremities
Only CurveBeam systems offer a wide platform that lets patients stand naturally during a scan along the lower extremity from the hip & pelvis to the feet. Oct 01, 2020
First Episealer Surgery Performed in the U.S.
The surgery was performed within the company's Investigational Device Exemption (IDE) clinical trial, EPIC-Knee: Episealer Knee System IDE Clinical Study. Oct 01, 2020
DJO Launches AltiVate Anatomic CS EDGE Stemless Shoulder
The canal-sparing AltiVate Anatomic CS EDGE Shoulder is designed to provide a less invasive, more bone-sparing solution for shoulder replacement. Sep 30, 2020
First Unity Knee with OMNIBotics Cases in the U.S.
Corin's Unity Knee with the OMNIBotics Predictive Balance robotic-assisted technique may help deliver balance and stability in total knee replacement. Sep 30, 2020
Medacta Launches 3DMetal Femoral Cones for Knee Revision
Medacta commenced commercial use of 3DMetal Femoral Cones for revision knee arthroplasty following FDA 510(k) clearance and approval under the CE Mark. Sep 30, 2020
Seikagaku Signs Marketing Agreement for OA Treatment
Eisai and Seikagaku will co-develop and market the SI-613 sodium hyaluronate therapeutic agent in South Korea for the treatment of knee osteoarthritis. Sep 30, 2020
